FIELD: biology, medicine.
SUBSTANCE: invention proposes using the tissue factor (TF) inhibitor in preparing a medicinal agent for treatment or prophylaxis of insulin-secreting cells transplant rejection, for treatment or prophylaxis of immediate blood-mediated inflammatory response (IBMIR) and corresponding methods for treatment. Nicotinamide, enalapril, and arginine that are TF inhibitors reduced synthesis and secretion of TF, and TF is a trigger mechanism for IBMIR, and anti-TF and iFVIIa block IBMIR initiated by human Langerhans islets. Inhibition of this response before carrying out the clinic transplantation of Largenhans islets can provide decreasing loss of transplanted tissue in the absence of harmful effect on the patient hemostasis.
EFFECT: valuable medicinal properties of inhibitor.
13 cl, 8 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PREVENTION OF FORMATION AND/OR STABILISATION OF THROMBI | 2005 |
|
RU2514878C2 |
| VASCULARISATION MODULATION TECHNIQUE | 2005 |
|
RU2378006C2 |
| STANDARD DRUG PREPARATIONS AND METHODS OF TREATING THROMBOSIS BY ORAL ADMINISTRATION OF FACTOR XA INHIBITOR | 2007 |
|
RU2452484C2 |
| NEW TISSUE FACTOR ANTIBODIES AS ANTICOAGULANTS | 2003 |
|
RU2345789C2 |
| MODIFIED FACTOR VII | 1995 |
|
RU2214833C2 |
| ANTIBODIES AGAINST INHIBITOR OF TISSUE FACTOR METABOLIC PATHWAY | 2009 |
|
RU2562114C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING FACTOR VII POLYPEPTIDES AND PAI-1 POLYPEPTIDES | 2002 |
|
RU2304980C2 |
| GLA DOMAINS AS THERAPEUTIC AGENTS | 2014 |
|
RU2705786C2 |
| METHOD FOR DETERMINING THE INHIBITORY POTENTIAL OF BLOOD FOR PREDICTING UNCONTROLLED ACTIVATION OF COMPLEMENT SYSTEM IN COVID-19 | 2023 |
|
RU2814496C1 |
| APPLICATION OF FVIIa OR TISSUE FACTOR ANTAGONIST TO REGULATE GENE EXPRESSION AND CELL JOURNEY OR CHEMOTAXIS | 2000 |
|
RU2268744C2 |
